the-infoshop.com - The vertical markets research portal
View CartView Cart
Global Information, Inc.
US: +1-860-674-8796
EU: +32-2-535-7543
SG: +65-6223-2436
  Home | Catalog | E-mail Alert | Custom Research | About The Infoshop | Contact Us | Site Map |

* View All Categories
Japanese Korean Chinese

[Report]

Strategic Analysis of Downstream Processing in Biopharmaceutical Production

Published: 2004/09

Contact 24 hrs/day
Table of Contents

Strategic Analysis of Downstream Processing in Biopharmaceutical Production

Research Overview

Increased Demand for New Solutions Drives Biopharmaceuticals Market

Accounting for over forty percent of biopharmaceutical manufacturing costs, downstream processing has been a long-standing market barrier. Low investment due to a lack of interest by participants has resulted in a technology bottleneck through a deficiency of specialized, high-throughput apparatus and automation systems. Despite this setback, the biopharmaceuticals market is expected to grow rapidly due to the lowering efficacy of existing drugs that is increasing the demand for treatment of new diseases. To effectively exploit this growing demand, industry focus is shifting towards technical specialization and investments in automated systems. Innovative downstream processing technologies are currently being developed to process new biopharmaceuticals.

Frost & Sullivanfs recent strategic analysis on downstream processing in biopharmaceuticals production offers a comprehensive overview of downstream processing technology dynamics and the market for contract manufacturing organisations (CMOs).

CMOs Vital to Defeat High Cost of In-house Downstream Processing

As in-house downstream processing technologies are an expensive investment, participants are outsourcing to CMOs. This is resulting in their gaining prominence in the constantly evolving biopharmaceuticals market. "Considered a key component of the biopharmaceuticals value chain, CMOs are being used by biopharmaceuticals companies to source key intermediates and active ingredients," says the analyst of this research. "The idea behind this strategic move is to speed the development of new patented products and decrease time-to-market while also providing the maximum cost efficiency and highest possible level of innovation."

CMOs, mostly distributed across the United States, United Kingdom and Germany, are currently investing heavily to develop their own facilities and market leaders are offering integrated downstream processing solutions for in-house use by major biopharmaceuticals companies.

Shift in R&D Focus Advantageous to the Global CMO Market

  • A shift in R&D focus from upstream processing and drug discovery to downstream processing ? which had earlier suffered from a lack of investment and innovation ? is likely to benefit the world CMO market immensely. "As the cost of installing or developing in-house downstream systems and staying abreast of technology developments is an expensive proposition, R&D and drug discovery firms are now outsourcing different stages of manufacturing to CMOs. Those CMOs which invest in downstream processing facilities are likely to benefit from this trend," says the analyst.

Frost & Sullivan Growth Partnership Service

Based on extensive and in-depth research, real-world consulting work, and new theories tested in hundreds of companies across many industries, Frost & Sullivan has evolved its Growth Partnership Services (GPS) program that provides established and emerging firms with powerful growth visions. Moving beyond token mission statements, GPS provides an actionable vision to growth consulting partners by illustrating how key intelligence and strategic research based on defined goals can guide day-to-day behavior and overall company direction. The foundation of Frost & Sullivan's GPS includes:

  • Assisting companies to reach their full potential in the core business
  • Providing growth strategies to help companies expand into related businesses
  • Preemptively redefining the core business during market turbulence
  • Applying the Frost & Sullivan framework to identify and address common mistakes resulting from misaligned corporate strategies
  • Recommending growth management strategies through continuous partnership

To maximize the potential for growth within a firmfs internal and external environment, Frost & Sullivan consultants can facilitate the creation of strategic programs that deliver improved market success. Frost & Sullivanfs strengths lie in combining strategic understanding with market expertise and applying these with absolute commitment to its clientsf growth.

Table of Contents

[Report]
Strategic Analysis of Downstream Processing in Biopharmaceutical Production
Published: 2004/09
Published by : Frost & Sullivan Frost & Sullivan

Price:
US $ 4,950.00 Web Access
US $ 5,450.00 Hard Copy & Web Access (Regional License)
>
Product Code : FS24223
Please inform me when related publications are released
InfoWatch

Available 24 Hours a Day
US: 1-860-674-8796 EU: 32-2-535-7543 SG: 65-6223-2436
The vertical markets research portal
© 2008, the-infoshop.com by Global Information, Inc. All rights reserved.